Argus raised the firm’s price target on CME Group to $245 from $225 and keeps a Buy rating on the shares. The analyst is citing the company’s Q4 earnings beat and expectations for further growth in interest rate contract volume despite the end of the Fed’s rate hike campaign. Argus is also raising its FY24 EPS view to $9.79 from $9.47.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CME:
- CME Group reports February ADV of 29.6M contracts
- CME Group to launch Micro Euro-denominated Bitcoin, Ether futures on 3/18
- CME Group price target raised to $225 from $222 at Barclays
- CME Group reports Q4 adjusted EPS $2.37, consensus $2.28
- CME Group Inc. Reports Fourth-Quarter and Full-Year 2023 Financial Results